Abstract
Resistance to cytotoxic chemotherapy continues to be a major obstacle to more effective treatment of human cancers. A particular problem in clinical cancer chemotherapy is the phenomenon of simultaneous resistance of cancers to a variety of unrelated cytotoxic agents. Such resistance to multiple drugs is observed much more often than resistance to individual compounds. A similar experimental phenomenon has been termed multidrug resistance or MDR. Much has been learned in recent years about molecular mechanisms which can lead to MDR in cancer cells and a number of studies has been performed to evaluate the clinical relevance of such mechanisms. In particular, P-glycoprotein-associated MDR (MDR1) has received a lot of attention. This review will discuss (i) some principal aspects of drug resistance in cancer with particular emphasis on MDR1; (ii) available data on drug resistance mechanisms in brain tumors; and (iii) our current knowledge on the putative role of P-glycoprotein in the blood-brain barrier.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Moscow JA, Cowan KH: Multidrug resistance. J Natl Cancer Inst 80: 14–20, 1988
Beck WT: The cell biology of multiple drug resistance. Biochem Pharmacol 36: 2870–2887, 1987
Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 62: 385–427, 1993
Cordon-Cardo C, O'Brien JP, Bocchia J, Casals D, Bertino JR, Melamed MR: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277–1287, 1990
Chaudhary PM, Roninson IB: Expression and activity of Pglycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66: 85–94, 1991
Chaudhary PM, Mechetner EB, Roninson IB: Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 11: 2735–2739, 1992
Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86: 695–698, 1989
Arceci RJ: Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 81: 2215–2222, 1993
Chan HSL, Thorner PS, Haddad G, Ling V: Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8: 689–704, 1990
Chan HSL, Haddad G, Thorner PS, DeBoer G, Lin YP, Ondrusek N, Yeger H, Ling V: P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325: 1608–1614, 1991
Ford JM, Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155–199, 1990
Sikic BI: Modulation of multidrug resistance: At the threshold. J Clin Oncol 11: 1629–1635, 1993
Lehnert M: Reversal of P-glycoprotein-associated multidrug resistance: The challenge continues. Eur J Cancer 29A: 636–638, 1993
Lehnert M: Reversal of multidrug resistance in breast cancer: Many more open questions than answers. Ann Oncol 4: 11–13, 1993
Lehnert M: Reversal of P-glycoprotein-associated multidrug resistance: From bench to bedside. Onkologie 17: 8–15, 1994
Lum BL, Kraubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, Sikic BI: Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10: 1635–1642, 1992
Levin VA, Gutin PH, Leibel S: Neoplasms of the central nervous system. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer, Principles and Practice of Oncology. JB Lippincot Company, Philadelphia 1679–1737, 1993
Philips PC: Antineoplastic drug resistance in brain tumors. Neurol Clin 9: 383–404, 1991
Becker I, Becker KF, Meyermann R, Höllt V: The multidrug resistance gene MDR1 is expressed in human glial tumors. Acta Neuropathol 82: 516–519, 1991
Nabors MW, Griffin CA, Zehnbauer BA, Hruban RH, Philips PC, Grossmann SA, Brem H, Colvin M: Multidrug resistance gene (MDR1) expression in human brain tumors. J Neurosurg 75: 941–946, 1991
Bodell WJ, Aida T, Berger MS, Rosenblum ML: Increased repair of 06-alkylguanine DNA adducts in glioma-derived human cells resistant to the cytotoxic and cytogenetic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea. Carcinogenesis 7: 879–883, 1986
Hegmann EJ, Bauer HC, Kerbel RS: Expression and functional activity of P-glycoprotein in cultured cerebral capillary endothelial cells. Cancer Res 52: 6969–6975, 1992
Schlosshauer B: The blood-brain barrier: Morphology, molecules, and neurothelin. BioAssays 15: 341–346, 1993
Zweit J, Carnochan P, Goodall R, Ott RJ: Excitation functions of proton induced reactions on cobalt: Production of no-carrier added Nickel-57, a positron emitting label for doxorubicin. Appl Radiat Isot 44: 1411–1416, 1993
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lehnert, M. Multidrug resistance in human cancer. J Neuro-Oncol 22, 239–243 (1994). https://doi.org/10.1007/BF01052927
Issue Date:
DOI: https://doi.org/10.1007/BF01052927